1. Scrip

Citius Pharmaceuticals Names Myron Holubiak To Board

 
• By Lubna Ahmed

Citius Pharmaceuticals has appointed former president of Roche Laboratories, Inc., USA, Myron Holubiak to its board – effective Oct. 1, 2015. Prior to being president, Holubiak held sales and marketing positions at Roche. Currently he is chair of the board at BioScrip, Inc., a member of the board of Assembly Biosciences, Inc.; and its predecessor Ventrus Biosciences, Inc.; and is also a founder of Leonard-Meron Biosciences, Inc., as well as its director and CEO.

Citius Pharmaceuticals has appointed former president of Roche Laboratories, Inc., USA, Myron Holubiak to its board – effective Oct. 1, 2015. Prior to being president, Holubiak held sales and marketing positions at Roche. Currently he is chair of the board at BioScrip, Inc., a member of the board of Assembly Biosciences, Inc.; and its predecessor Ventrus Biosciences, Inc.; and is also a founder of Leonard-Meron Biosciences, Inc., as well as its director and CEO.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.